Comparative Pharmacology
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus VISTARIL.
MECLIZINE HYDROCHLORIDE vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category A/B
Category C
Antihistamine
Antihistamine